The stock of Monte Rosa Therapeutics Inc (GLUE) has seen a -1.82% decrease in the past week, with a -5.54% drop in the past month, and a -48.73% decrease in the past quarter. The volatility ratio for the week is 10.45%, and the volatility levels for the past 30 days are at 11.52% for GLUE. The simple moving average for the past 20 days is 2.76% for GLUE’s stock, with a -46.58% simple moving average for the past 200 days.

Is It Worth Investing in Monte Rosa Therapeutics Inc (NASDAQ: GLUE) Right Now?

Additionally, the 36-month beta value for GLUE is 1.17. There are mixed opinions on the stock, with 8 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”

The average price predicted by analysts for GLUE is $16.50, which is $13.26 above the current price. The public float for GLUE is 31.41M and currently, short sellers hold a 10.66% ratio of that float. The average trading volume of GLUE on November 17, 2023 was 263.09K shares.

GLUE) stock’s latest price update

Monte Rosa Therapeutics Inc (NASDAQ: GLUE)’s stock price has dropped by -11.96 in relation to previous closing price of 3.68. Nevertheless, the company has seen a loss of -1.82% in its stock price over the last five trading days. GlobeNewsWire reported 2023-10-27 that BOSTON, Oct. 27, 2023 (GLOBE NEWSWIRE) — Monte Rosa Therapeutics, a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will participate in the following investor conferences: TD Cowen 7th Annual Fall Oncology Innovation Summit (virtual) – Fireside Chat, November 3, 2023, 1:00 p.m. ET Jefferies London Healthcare Conference (London, UK) – Investor meetings, November 14-15, 2023 The webcasted presentation will be accessible via the “Events & Presentations” section of Monte Rosa’s website at, and an archived version will be made available for 90 days following the presentation.

Analysts’ Opinion of GLUE

Many brokerage firms have already submitted their reports for GLUE stocks, with Wells Fargo repeating the rating for GLUE by listing it as a “Overweight.” The predicted price for GLUE in the upcoming period, according to Wells Fargo is $18 based on the research report published on January 03, 2023 of the current year 2023.

GLUE Trading at -27.02% from the 50-Day Moving Average

After a stumble in the market that brought GLUE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -68.36% of loss for the given period.

Volatility was left at 11.52%, however, over the last 30 days, the volatility rate increased by 10.45%, as shares surge +3.68% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -46.00% lower at present.

During the last 5 trading sessions, GLUE fell by -1.82%, which changed the moving average for the period of 200-days by -55.19% in comparison to the 20-day moving average, which settled at $3.16. In addition, Monte Rosa Therapeutics Inc saw -57.42% in overturn over a single year, with a tendency to cut further losses.

Stock Fundamentals for GLUE

The total capital return value is set at -33.75, while invested capital returns managed to touch -32.74. Equity return is now at value -55.88, with -43.59 for asset returns.

Based on Monte Rosa Therapeutics Inc (GLUE), the company’s capital structure generated 17.32 points at debt to equity in total, while total debt to capital is 14.76. Total debt to assets is 13.73, with long-term debt to equity ratio resting at 16.17. Finally, the long-term debt to capital ratio is 13.78.

The liquidity ratio also appears to be rather interesting for investors as it stands at 10.79.


In conclusion, Monte Rosa Therapeutics Inc (GLUE) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.